New Delhi:The Indian Pharmaceutical Market (IPM) grew 8.7% in August 2025, reaching Rs 20,984 crore in value, according to the latest PharmaTrac Industry Report by Pharmarack. In unit terms, the market expanded by 1.2%, underscoring steady demand despite volume stagnation. Growth in August was largely price-driven, supported by new product launches and seasonal therapies. Therapy-wise, the respiratory segment recorded the strongest growth at 17.3%, driven by seasonal factors. Antineoplastics grew by 19.7%, while urology registered 14.6% growth. Cardiac therapies expanded by 13.2%, and blood-related therapies rose 10% in the month. Anti-diabetic therapies increased by 9.4%, while gastrointestinal products reported 7.1% growth and vitamins and minerals advanced by 5.7%. Neuro/CNS therapies grew by 8.3%, dermatology by 8.7%, and anti-infectives by 8.2%. Vaccines posted a strong rebound, growing 21.4% during the month. At the corporate level, Sun Pharma maintained its leadership with sales of ₹19,542 crore, reflecting 13.7% growth in August. Abbott followed with ₹13,723 crore in sales, up 8.4%, while Mankind Pharma posted sales of ₹13,326 crore, registering 9.6% growth. Other leading companies including Cipla, Alkem, Intas, Torrent, Lupin, Dr. Reddy’s, and Zydus also posted healthy growth in the range of 7% to 13%. The Top 20 list additionally featured Macleods, Aristo, Emcure, GSK, Glenmark, USV, IPCA, Micro Labs, Pfizer, and Eris Lifesciences, all of which registered positive momentum in August. At the brand level, Augmentin (GSK), Glycomet GP (USV), Pan (Alkem), and Mixtard (Abbott) continued to dominate the market in August. Himalaya’s Liv.52 grew by 13.9%, while Alkem’s Pan D rose 15.3%. Innovative therapies also performed strongly, with Abbott’s Ryzodeg up 17.4% and Thyronorm rising 16.3%. Other brands featuring in the top-selling list included Clavam, Monocef, Udiliv, Zerodol SP, Betadine, Telma, Manforce, Cilacar, Electral, Ultracet, and Duolin. Also Read: Post-Patent Expiry Boom, Empagliflozin Sees Brand Flood, 147 Brands Launched: Pharmatrac
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!